Dale Chappell

919 total citations
11 papers, 34 citations indexed

About

Dale Chappell is a scholar working on Infectious Diseases, Neurology and Oncology. According to data from OpenAlex, Dale Chappell has authored 11 papers receiving a total of 34 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Infectious Diseases, 4 papers in Neurology and 4 papers in Oncology. Recurrent topics in Dale Chappell's work include COVID-19 Clinical Research Studies (6 papers), Long-Term Effects of COVID-19 (4 papers) and CAR-T cell therapy research (3 papers). Dale Chappell is often cited by papers focused on COVID-19 Clinical Research Studies (6 papers), Long-Term Effects of COVID-19 (4 papers) and CAR-T cell therapy research (3 papers). Dale Chappell collaborates with scholars based in United States, United Kingdom and Switzerland. Dale Chappell's co-authors include Adrian Kilcoyne, Cameron Durrant, Omar Abdihamid, Frank Cerasoli, Victoria M. Catterson, Christopher Polk, Andrew D. Badley, Allen S. Zhou, Saad S. Kenderian and Amalia Tsiami and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and CHEST Journal.

In The Last Decade

Dale Chappell

9 papers receiving 32 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dale Chappell United States 4 15 13 9 6 5 11 34
Adrian Kilcoyne United States 6 13 0.9× 21 1.6× 8 0.9× 7 1.2× 12 2.4× 9 45
Giuseppina Affinito Italy 6 10 0.7× 13 1.0× 12 1.3× 2 0.3× 4 0.8× 15 58
Tina Parciak Germany 4 19 1.3× 9 0.7× 20 2.2× 3 0.5× 6 1.2× 5 60
Alireza Kashefizadeh Iran 4 11 0.7× 12 0.9× 5 0.6× 6 1.2× 10 32
Victor M. Orellana‐Noia United States 4 7 0.5× 17 1.3× 10 1.1× 4 0.8× 13 34
Jaime Valentín Quiroga Spain 3 9 0.6× 11 0.8× 5 0.6× 2 0.4× 4 26
Justine Jia Wen Seow Singapore 4 23 1.5× 11 0.8× 12 1.3× 1 0.2× 13 2.6× 5 51
Amin Khattab Saudi Arabia 3 29 1.9× 14 1.1× 13 1.4× 2 0.3× 7 1.4× 3 44
Marina Kosinova Russia 3 5 0.3× 4 0.3× 6 0.7× 3 0.5× 6 1.2× 7 28
Adrian Pace United Kingdom 3 7 0.5× 12 0.9× 8 0.9× 9 1.8× 5 36

Countries citing papers authored by Dale Chappell

Since Specialization
Citations

This map shows the geographic impact of Dale Chappell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dale Chappell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dale Chappell more than expected).

Fields of papers citing papers by Dale Chappell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dale Chappell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dale Chappell. The network helps show where Dale Chappell may publish in the future.

Co-authorship network of co-authors of Dale Chappell

This figure shows the co-authorship network connecting the top 25 collaborators of Dale Chappell. A scholar is included among the top collaborators of Dale Chappell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dale Chappell. Dale Chappell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Kilcoyne, Adrian, et al.. (2022). Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVID-19) from the Perspective of National Health Service England. SHILAP Revista de lepidopterología. 3 indexed citations
2.
Temesgen, Zelalem, Colleen F. Kelley, Frank Cerasoli, et al.. (2022). C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial. Thorax. 78(6). thoraxjnl–2022. 8 indexed citations
3.
4.
Kenderian, Saad S., Cameron Durrant, Dale Chappell, Omar Abdihamid, & Adrian Kilcoyne. (2021). A Phase 2/3 Randomized, Placebo-Controlled, Open-Label, Multi-Center Trial of Lenzilumab to Improve the Safety and Efficacy of CAR-T Cell Therapy in Adults with Relapsed or Refractory Large B-Cell Lymphoma (The SHIELD Study). Blood. 138(Supplement 1). 1758–1758. 5 indexed citations
5.
6.
Temesgen, Zelalem, Charles D. Burger, Jason V. Baker, et al.. (2021). C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN PATIENTS WITH COVID-19: RESULTS FROM THE LIVE-AIR TRIAL. CHEST Journal. 160(4). A2522–A2524.
7.
Burger, Charles D., Jason V. Baker, Christopher Polk, et al.. (2021). 40. Lenzilumab Efficacy and Safety in Newly Hospitalized COVID-19 Subjects: Results From a Phase 3 Randomized Double-Blind Placebo-Controlled Trial. Open Forum Infectious Diseases. 8(Supplement_1). S29–S29.
8.
Cox, Michelle J., Rosalie M. Sterner, Reona Sakemura, et al.. (2020). Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carts. Biology of Blood and Marrow Transplantation. 26(3). S60–S61. 3 indexed citations
9.
Cox, Michelle J., Rosalie M. Sterner, Reona Sakemura, et al.. (2019). Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carts. Blood. 134(Supplement_1). 3868–3868. 3 indexed citations
10.
Patnaik, Mrinal M., David A. Sallman, Abhishek A. Mangaonkar, et al.. (2019). A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti-Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocytic Leukemia (CMML). Blood. 134(Supplement_1). 4234–4234. 3 indexed citations
11.
Chappell, Dale, et al.. (2015). Efficacy of Methylcobalamin to Normalise Elevated Homocysteine of Vitamin B12 Deficient Vegetarians: A Double Blind Placebo Control Study. Current Research in Nutrition and Food Science Journal. 3(3). 187–196. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Adrian Kilcoyne Breakdown of academic impact, for papers by Giuseppina Affinito Breakdown of academic impact, for papers by Tina Parciak Breakdown of academic impact, for papers by Alireza Kashefizadeh Breakdown of academic impact, for papers by Victor M. Orellana‐Noia Breakdown of academic impact, for papers by Jaime Valentín Quiroga Breakdown of academic impact, for papers by Justine Jia Wen Seow Breakdown of academic impact, for papers by Amin Khattab Breakdown of academic impact, for papers by Marina Kosinova Breakdown of academic impact, for papers by Adrian Pace
Rankless by CCL
2026